News

Boehringer Ingelheim and the Scleroderma  Foundation have started a global initiative to raise awareness of scleroderma and support those with the life-threatening disease. In conjunction with the initiative, which is dubbed More Than Scleroderma: The Inside Story, they created a website that will feature the latest scientific knowledge and news on…

A rock-painting contest in Las Vegas. A fashion show in New York. A 7,000-meter race around the Washington Monument that’ll coincide with a similar #Racefor7 event in Bengaluru and Mumbai, India. From Athens to Atlanta, from San Diego to Sydney, people across the globe will mark World Rare Disease…

The European Medicines Agency has granted orphan drug designation to Emerald Health Pharmaceuticals’  lead cannabis-based product for treating systemic scleroderma. EHP-101 is derived from cannabidiol, a chemical found in the cannabis plant. The therapy activates the cell-surface receptors PPARγ and CB2, which in turn activate cell signaling pathways that can…

The National Institutes of Health’s (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) recently awarded five new Core Centers for Clinical Research (CCCR), one of them with a particular focus on scleroderma. The goal of the CCCRs is to develop and apply methods that…

David Curtis Glebe, a retired 64-year-old public prosecutor now living in Millsboro, Delaware, knows he’s lucky to be alive. In mid-2013, while in Arizona, Glebe was diagnosed with pancreatic neuroendocrine cancer (PNET) — the same disease that killed Apple’s founder and CEO Steve Jobs. After three years of progress…

Immunosuppressive therapy followed by an autologous stem cell transplant resulted in significant long-term benefits, including improved overall survival, in adult scleroderma patients compared to immunosuppressive therapy alone, according to the results of a Phase 2/3 trial. Despite a higher rate of treatment-related deaths in the transplant group, researchers argue…

Fibrocell Science has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for FCX-013, its gene therapy candidate for moderate to severe localized scleroderma. An IND is a request for FDA authorization to administer an investigational therapy to humans. It is generally…

Should their doctors agree, breast cancer patients with scleroderma may undergo radiation therapy — despite research suggesting it increases the risk of scarring in the skin, lungs and other organs, a team of American scientists has concluded. The previous studies’ small sample size — fewer than four patients — makes…

This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…

New research establishes a link between immune cells, known as macrophages, and systemic sclerosis progression. The study showed that gene expression in macrophages from systemic sclerosis patients is altered, including higher activity of the susceptibility gene GSDMA. The study “Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution…